450 Participants Needed

RTX-GRT7039 Injection for Osteoarthritis

Recruiting at 92 trial locations
Dc
Overseen ByDirector clinical trials
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Grünenthal GmbH
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a special injection called RTX-GRT7039 to help reduce knee pain in people with osteoarthritis who still have pain despite usual treatments. The injection works by blocking pain signals from the knee.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

How is RTX-GRT7039 different from other osteoarthritis treatments?

RTX-GRT7039 is unique because it is being tested as an injection specifically for osteoarthritis, potentially offering a new approach compared to existing treatments like hyaluronic acid or corticosteroids, which are also injected but have different active ingredients and mechanisms.12345

What data supports the effectiveness of the treatment RTX-GRT7039 Injection for Osteoarthritis?

Research shows that placebo injections can have a significant effect on reducing pain and improving function in knee osteoarthritis, suggesting that the act of receiving an injection itself can contribute to symptom relief.12467

Are You a Good Fit for This Trial?

Adults over 18 with knee osteoarthritis who haven't found pain relief from standard treatments can join. They must understand and agree to the trial's process. Excluded are those with severe joint damage, past knee surgery within a year, significant leg misalignment, other conditions affecting safety or results, recent participation in another drug trial, employees involved in the study, clinical hip osteoarthritis on the same side, or allergy to resiniferatoxin.

Inclusion Criteria

You have tried the usual treatments for your pain, but they did not work well enough for you.
The participant has a diagnosis of osteoarthritis of the knee based on American College of Rheumatology criteria and functional capacity class of I to III.
The participant has given written informed consent to participate.

Exclusion Criteria

You have certain existing bone conditions or severe knee pain that is not caused by osteoarthritis.
You have hip osteoarthritis on the same side as your knee condition.
The participant has past joint replacement surgery of the index knee.
See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single intra-articular injection of RTX-GRT7039 or placebo during the 52-week double-blind treatment period

52 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Placebo
  • RTX-GRT7039
Trial Overview The trial is testing RTX-GRT7039 against a placebo for knee osteoarthritis pain relief. Participants will receive one injection and be randomly assigned to either the treatment or placebo group without knowing which they received (double-blind). The goal is to confirm if RTX-GRT7039 is effective and safe.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: RTX-GRT7039Experimental Treatment1 Intervention
Participants will receive a intra-articular injection of RTX-GRT7039 during the 52-week double-blind treatment period.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive a intra-articular injection of placebo matching RTX-GRT7039 during the 52-week double-blind treatment period.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Grünenthal GmbH

Lead Sponsor

Trials
99
Recruited
34,200+

Gabriel Baertschi

Grünenthal GmbH

Chief Executive Officer since 2016

Biology degree from the University of Neuchâtel

Prof. Dr. Uli Brödl

Grünenthal GmbH

Chief Medical Officer

MD from Ludwig-Maximilians University Munich

Citations

A prospective, randomized, double-blind, placebo controlled study to evaluate the efficacy of intraarticular hyaluronic acid for osteoarthritis of the knee. [2016]
The Long-Lasting Effects of "Placebo Injections" in Knee Osteoarthritis: A Meta-Analysis. [2022]
Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint. [2022]
Predictors of Placebo Response to Local (Intra-Articular) Therapy In Osteoarthritis: An Individual Participant Data Meta-Analysis. [2023]
Localized Injection of Streptomycin, Kenacort and Lidocaine combination for Symptomatic Pain Management of Knee Osteoarthritis. [2019]
Intra-articular Corticosteroids for Osteoarthritis of the Knee. [2018]
Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security